Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05527821 Not yet recruiting - Clinical trials for Unresectable Advanced Solid Tumors

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Start date: September 30, 2022
Phase: Phase 2
Study type: Interventional

An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors

NCT ID: NCT05526534 Recruiting - Gynecologic Surgery Clinical Trials

A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Patients at high risk of post-operative pulmonary complications (PPC) will be screened out from gynecological tumor patients undergoing surgical treatment, and randomly assigned into the HFNC group and control group, which uses conventional nasal cannula oxygen therapy. The primary outcome is the incidence of PPC, including postoperative hypoxemia, atelectasis, pneumonia, etc. Secondary outcomes are the improvement of postoperative oxygenation, antibiotic use, length of hospital stay, adverse events related to oxygen therapy, etc.

NCT ID: NCT05525858 Recruiting - Solid Tumor Clinical Trials

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

KOSMOSII
Start date: September 28, 2022
Phase:
Study type: Observational

A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using targeted and/or immunotherapies outside of the approved indications via local clinical practice (Tier 1 & 2) and clinical trials (Tier 3)

NCT ID: NCT05525559 Not yet recruiting - Clinical trials for Advanced Solid Tumor

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

FIRST
Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors. It is anticipated that approximately 34 subjects will be enrolled in the dose-escalation phase of the study. ET0038 will be administered orally once daily (QD) in 21-day treatment cycles.

NCT ID: NCT05525455 Terminated - Cancer Clinical Trials

TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)

Start date: August 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.

NCT ID: NCT05524857 Terminated - Clinical trials for Myeloproliferative Neoplasm

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Start date: January 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this research is to study the safety and tolerability and to establish the maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for the treatment of advanced-phase MPNs.

NCT ID: NCT05524194 Not yet recruiting - Solid Tumors Clinical Trials

6MW3511 in Patients With Advanced Solid Tumor

Start date: October 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II , open-label, multicenter single arm study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and immunogenicity of 6MW3511.

NCT ID: NCT05523947 Recruiting - Clinical trials for HER2-Positive Solid Tumor

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Start date: August 26, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.

NCT ID: NCT05523154 Active, not recruiting - Clinical trials for Malignant Pancreatic Neoplasm

"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures

Start date: January 19, 2023
Phase: Early Phase 1
Study type: Interventional

This early phase I trial evaluates nanopore sequencing for its ability to detect bacteria in bile and prevent surgical site infections in patients undergoing surgery for benign or malignant pancreatic tumors. Surgical site infections are a significant source of poor outcomes in patients undergoing surgery for pancreatic tumors. In most patients who develop this kind of infection, the bacteria identified as causing the infection is also frequently found to be in the bile at time of surgery. Using nanopore sequencing to detect bacteria in the bile of patients undergoing surgery may allow doctors to prevent surgical site infections or treat them sooner or more effectively.

NCT ID: NCT05522868 Recruiting - Solid Tumor Clinical Trials

SB17170 Phase 1 Clinical Trial in Solid Tumors

Start date: October 17, 2022
Phase: Phase 1
Study type: Interventional

Phase 1 Open-label, multicenter, dose escalation, dose expansion study